An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom

Value in Health

Volumn 11, Issue 5, 2008, Pages 791-799

  Brown, Ben ^a   Diamantopoulos, Alexander ^a   Bernier, Jacques ^b   Schöffski, Patrick ^c   Hieke, Klaus ^d   Mantovani, Lorenzo ^e,f   Launois, Robert ^g   Griebsch, Ingolf ^h   Robinson, Paul ^a  

^a IQVIA   (United States)

^b CLINIQUE DE GENOLIER   (Switzerland)

^c Katholieke Universiteit   (Belgium)

^d NEOS Health   (Switzerland)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f Fondazione Charta   (Italy)

^g REES France   (France)

^h MERCK KGAA   (Germany)

Author keywords

Cetuximab; Economic; Head and neck cancer; Models; Quality adjusted life years; Radiotherapy

Indexed keywords

CETUXIMAB;

ACNE; ADVANCED CANCER; ANEMIA; ARTICLE; BELGIUM; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEHYDRATION; DRUG COST; DYSPHAGIA; ECONOMIC EVALUATION; FEBRILE NEUTROPENIA; FEVER; FRANCE; HEAD AND NECK CANCER; HEALTH CARE COST; HUMAN; INFECTION; ITALY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; SENSITIVITY ANALYSIS; SIDE EFFECT; STOMATITIS; SWITZERLAND; THROMBOCYTOPENIA; UNITED KINGDOM; VOMITING; WEIGHT REDUCTION;

EID: 50049111116     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00302.x     Document Type: Article

References (24)

1. Lefebvre JL. Current clinical outcomes demand new treatment options for SCCHN. Ann Oncol 2005 16 (Suppl. 6 S7 i12.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999 80 : 827 41.
3. Argiris A. Update on chemoradiotherapy for head and neck cancer. Curr Opin Oncol 2002 14 : 323 9.
4. Seiwert TY, Cohen EE. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 2005 92 : 1341 8.
5. Harari PM, Ritter MA, Petereit DG, Mehta MP. Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. Curr Probl Cancer 2004 28 : 7 40.
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers, Report No.: V.1.2006. Jenkintown, PA : National Comprehensive Cancer Network, 2006.
7. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002 62 : 7350 6.
8. Bernier J, Schneider D. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck? Eur J Cancer 2007 43 : 35 45.
9. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006 354 : 567 78.
10. Drummond MF, Mason AR. European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Oncol 2007 25 : 191 5.
11. Lee JM, Turini M, Botteman MF, et al. Economic burden of head and neck cancer. A literature review. Eur J Health Econ 2004 5 : 70 80.
12. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes (3rd ed.). Oxford : Oxford University Press, 2005.
13. Tappenden P, Chilcott J, Ward S, et al. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer 2006 42 : 2867 75.
14. Perperoglou A, Keramopoullos A, van Houwelingen HC. Approaches in modelling long-term survival: an application to breast cancer. Stat Med 2007 6 : 2666 85.
15. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000 355 : 949 55.
16. Brazier J, Deverill M, Green C, et al. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999 3 : 1 164.
17. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997 35 : 1095 108.
18. Briggs AH. Handling uncertainty in economic evaluation. In : Drummond MF, McGuire A, eds. Economic Evaluation in Health Care. Oxford, NY : Oxford University Press, 2001.
19. Neymark N, Adriaenssen I, Gorlia T, et al. Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ 2002 11 : 233 48.
20. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004 329 : 224 7.
21. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004 7 : 518 28.
22. Posner MR, Wirth LJ. Cetuximab and radiotherapy for head and neck cancer. N Engl J Med 2006 354 : 634 6.
23. Braaksma MAM, Nijdam W, et al. Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine. Eur J Cancer 2005 41 : 2102 11.
24. Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003 98 : 1531 9.